Kidney transplant patients may think better with Once-Daily pill
NCT ID NCT04838288
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study tested if kidney transplant patients who switch from a twice-daily anti-rejection drug (tacrolimus) to a once-daily version (Envarsus XR) experience improvements in memory, attention, and overall quality of life. Fifty-six stable adult kidney transplant recipients were enrolled. Researchers measured cognitive function using phone-based tests and standard assessments before and after the switch.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
VUMC
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.